Join the club for FREE to access the whole archive and other member benefits.

This therapy attacks solid-tumor cancer cells in mice, humans


Key points from article :

A method known as CAR-T therapy has been used successfully in patients with blood cancers.

It modifies a patient's own T-cells by adding a piece of an antibody.

This antibody recognizes unique features on the surface of cancer cells.

Their engineered T-cells attack a variety of solid-tumor cancer cells from humans and mice.

A major challenge has been to identify targets that exist on cancer cells.

Particularly in solid tumors that are not present on normal tissue.

The team started with a piece of an antibody that could serve as a receptor..

Then engineered into T-cells and tested them with mouse and human cancer cell lines.

The T-cells can now recognize several different proteins that have short sugars attached to them.

Having multiple targets makes it very difficult for the cancer to evade the treatment.

Research from University of Illinois.

Published in the Proceedings of the National Academy of Sciences.

CAR-T therapy, a proven approach, now improved to broaden potential targets

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Professor of Biochemistry, PHILLIP A. SHARP Professor


Postdoctoral researcher at the University of Illinois


Multidisciplinary scientific journal, official journal of the National Academy of Sciences


Postdocoral researcher, Cancer Center, University of Illinois